Loading...

We've got a brand new version of Simply Wall St! Try it out

Lexaria Bioscience

CNSX:LXX
Snowflake Description

Adequate balance sheet and slightly overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
LXX
CNSX
$51M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

Lexaria Bioscience Corp. focuses on the development of its proprietary nutrient infusion technologies for the production of superfoods. The last earnings update was 76 days ago. More info.


Add to Portfolio Compare Print
  • Lexaria Bioscience has significant price volatility in the past 3 months.
LXX Share Price and Events
7 Day Returns
2.3%
CNSX:LXX
-5.9%
CA Pharmaceuticals
1.3%
CA Market
1 Year Returns
-66.2%
CNSX:LXX
-46.7%
CA Pharmaceuticals
-0.1%
CA Market
LXX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Lexaria Bioscience (LXX) 2.3% -3.3% -19.1% -66.2% 408.6% -
CA Pharmaceuticals -5.9% -3.4% -24.8% -46.7% 217.3% 286.4%
CA Market 1.3% 4.2% 1.6% -0.1% 8.4% 5.7%
1 Year Return vs Industry and Market
  • LXX underperformed the Pharmaceuticals industry which returned -46.7% over the past year.
  • LXX underperformed the Market in Canada which returned -0.1% over the past year.
Price Volatility
LXX
Industry
5yr Volatility vs Market

LXX Value

 Is Lexaria Bioscience undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Lexaria Bioscience to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Lexaria Bioscience.

CNSX:LXX Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 2 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.7%
Perpetual Growth Rate 10-Year CA Government Bond Rate 1.9%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for CNSX:LXX
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year CA Govt Bond Rate 1.9%
Equity Risk Premium S&P Global 6%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.7
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.698 (1 + (1- 26.5%) (0%))
0.798
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.95% + (0.8 * 5.96%)
6.72%

Discounted Cash Flow Calculation for CNSX:LXX using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Lexaria Bioscience is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

CNSX:LXX DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 6.72%)
2020 -2.30 Analyst x1 -2.16
2021 3.90 Analyst x1 3.42
2022 6.58 Est @ 68.62% 5.41
2023 9.77 Est @ 48.62% 7.54
2024 13.16 Est @ 34.62% 9.51
2025 16.42 Est @ 24.82% 11.12
2026 19.37 Est @ 17.95% 12.29
2027 21.92 Est @ 13.15% 13.03
2028 24.06 Est @ 9.79% 13.41
2029 25.85 Est @ 7.44% 13.50
Present value of next 10 years cash flows $87.00
CNSX:LXX DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $25.85 × (1 + 1.95%) ÷ (6.72% – 1.95%)
$552.76
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $552.76 ÷ (1 + 6.72%)10
$288.59
CNSX:LXX Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $87.00 + $288.59
$375.59
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $375.59 / 78.64
$4.78
CNSX:LXX Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in CNSX:LXX represents 1.36661x of OTCPK:LXRP
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
1.36661x
Value per Share
(Listing Adjusted, CAD)
= Value per Share (USD) x Listing Adjustment Factor
= $ 4.78 x 1.36661
CA$6.53
Value per share (CAD) From above. CA$6.53
Current discount Discount to share price of CA$0.89
= -1 x (CA$0.89 - CA$6.53) / CA$6.53
86.4%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Lexaria Bioscience is available for.
Intrinsic value
>50%
Share price is CA$0.89 vs Future cash flow value of CA$6.53
Current Discount Checks
For Lexaria Bioscience to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Lexaria Bioscience's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Lexaria Bioscience's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Lexaria Bioscience's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Lexaria Bioscience's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:LXX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-05-31) in USD $-0.06
OTCPK:LXRP Share Price ** OTCPK (2019-09-20) in USD $0.65
Canada Pharmaceuticals Industry PE Ratio Median Figure of 13 Publicly-Listed Pharmaceuticals Companies 15.3x
Canada Market PE Ratio Median Figure of 539 Publicly-Listed Companies 14.14x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Lexaria Bioscience.

CNSX:LXX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OTCPK:LXRP Share Price ÷ EPS (both in USD)

= 0.65 ÷ -0.06

-11.74x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Lexaria Bioscience is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • Lexaria Bioscience is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Lexaria Bioscience's expected growth come at a high price?
Raw Data
CNSX:LXX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -11.74x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
-1.2%per year
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 1.56x
Canada Market PEG Ratio Median Figure of 245 Publicly-Listed Companies 1.02x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Lexaria Bioscience, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Lexaria Bioscience's assets?
Raw Data
CNSX:LXX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-05-31) in USD $0.04
OTCPK:LXRP Share Price * OTCPK (2019-09-20) in USD $0.65
Canada Pharmaceuticals Industry PB Ratio Median Figure of 151 Publicly-Listed Pharmaceuticals Companies 2.36x
Canada Market PB Ratio Median Figure of 2,457 Publicly-Listed Companies 1.43x
CNSX:LXX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OTCPK:LXRP Share Price ÷ Book Value per Share (both in USD)

= 0.65 ÷ 0.04

16.07x

* Primary Listing of Lexaria Bioscience.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Lexaria Bioscience is overvalued based on assets compared to the CA Pharmaceuticals industry average.
X
Value checks
We assess Lexaria Bioscience's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Lexaria Bioscience has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

LXX Future Performance

 How is Lexaria Bioscience expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-1.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Lexaria Bioscience expected to grow at an attractive rate?
  • Unable to compare Lexaria Bioscience's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Lexaria Bioscience's earnings growth to the Canada market average as it is expected to be loss making during the next 1-3 years.
  • Lexaria Bioscience's revenue growth is expected to exceed the Canada market average.
Annual Growth Rates Comparison
Raw Data
CNSX:LXX Future Growth Rates Data Sources
Data Point Source Value (per year)
CNSX:LXX Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts -1.2%
CNSX:LXX Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 137.3%
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 97.7%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 56.5%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.6%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:LXX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:LXX Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-08-31 19 1
2020-08-31 2 -4 -4 2
2019-09-22
2019-08-31 0 -3 -4 2
CNSX:LXX Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-05-31 0 -3 -4
2019-02-28 0 -3 -6
2018-11-30 0 -3 -7
2018-08-31 0 -3 -7
2018-05-31 0 -2 -6
2018-02-28 0 -2 -3
2017-11-30 0 -2 -2
2017-08-31 0 -2 -2
2017-05-31 0 -1 -1
2017-02-28 0 -1 -1
2016-11-30 0 -1 -1
2016-08-31 0 -1 -1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Lexaria Bioscience is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Lexaria Bioscience's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:LXX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Lexaria Bioscience Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:LXX Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-08-31
2020-08-31 -0.05 -0.05 -0.05 1.00
2019-09-22
2019-08-31 -0.05 -0.05 -0.05 1.00
CNSX:LXX Past Financials Data
Date (Data in USD Millions) EPS *
2019-05-31 -0.06
2019-02-28 -0.09
2018-11-30 -0.09
2018-08-31 -0.09
2018-05-31 -0.09
2018-02-28 -0.04
2017-11-30 -0.03
2017-08-31 -0.03
2017-05-31 -0.03
2017-02-28 -0.03
2016-11-30 -0.03
2016-08-31 -0.03

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Lexaria Bioscience will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Lexaria Bioscience's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Lexaria Bioscience has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

LXX Past Performance

  How has Lexaria Bioscience performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Lexaria Bioscience's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Lexaria Bioscience does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Lexaria Bioscience's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Lexaria Bioscience's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Lexaria Bioscience's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Lexaria Bioscience Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:LXX Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-05-31 0.19 -4.24 3.74 0.61
2019-02-28 0.27 -6.49 6.27 0.47
2018-11-30 0.43 -6.72 6.64 0.48
2018-08-31 0.43 -6.60 6.51 0.49
2018-05-31 0.35 -6.07 6.04 0.31
2018-02-28 0.24 -2.98 2.89 0.23
2017-11-30 0.08 -2.05 1.85 0.16
2017-08-31 0.06 -1.87 1.74 0.05
2017-05-31 0.06 -1.50 1.41 0.02
2017-02-28 0.04 -1.42 1.35 0.02
2016-11-30 0.04 -1.23 1.15 0.01
2016-08-31 0.04 -1.21 1.18 0.01
2016-05-31 0.04 -1.42 1.35 0.11
2016-02-29 0.04 -1.63 1.60 0.11
2015-11-30 0.03 -1.81 1.82 0.10
2015-08-31 0.01 -1.82 1.74 0.15
2015-05-31 0.01 -2.38 2.12 0.05
2015-02-28 0.00 -2.44 2.09 0.05
2014-11-30 -2.13 1.75 0.05
2014-08-31 -1.87 1.52
2014-07-31 0.70 -1.30 1.25
2014-04-30 0.82 -0.78 0.76
2014-01-31 0.91 -0.33 0.37
2013-10-31 -0.63 0.37
2013-07-31 1.33 -0.19 0.39
2013-04-30 1.57 -0.06 0.44
2013-01-31 1.46 -0.24 0.51
2012-10-31 1.36 -0.25 0.54

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Lexaria Bioscience has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Lexaria Bioscience has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Lexaria Bioscience improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Lexaria Bioscience's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Lexaria Bioscience has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

LXX Health

 How is Lexaria Bioscience's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Lexaria Bioscience's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Lexaria Bioscience is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Lexaria Bioscience has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Lexaria Bioscience's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Lexaria Bioscience has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Lexaria Bioscience Company Filings, last reported 3 months ago.

CNSX:LXX Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-05-31 3.32 0.00 2.07
2019-02-28 3.77 0.00 3.16
2018-11-30 3.41 0.00 2.72
2018-08-31 2.39 0.00 1.74
2018-05-31 2.64 0.00 2.08
2018-02-28 2.77 0.00 2.32
2017-11-30 2.40 0.00 2.21
2017-08-31 2.77 0.00 2.53
2017-05-31 3.06 0.05 2.79
2017-02-28 0.49 0.05 0.52
2016-11-30 0.62 0.05 0.12
2016-08-31 0.09 0.05 0.09
2016-05-31 -0.05 0.05 0.04
2016-02-29 0.11 0.00 0.04
2015-11-30 0.32 0.00 0.08
2015-08-31 0.66 0.00 0.26
2015-05-31 1.14 0.00 0.83
2015-02-28 1.17 0.00 0.79
2014-11-30 1.46 0.00 0.43
2014-08-31 1.72 0.78 0.70
2014-07-31 3.55 0.81 0.58
2014-04-30 3.73 0.91 0.95
2014-01-31 2.03 1.29 0.03
2013-10-31 2.10 1.28 0.07
2013-07-31 2.23 1.30 0.03
2013-04-30 2.26 1.38 0.04
2013-01-31 2.31 1.48 0.04
2012-10-31 2.42 1.64 0.18
  • Lexaria Bioscience has no debt.
  • Lexaria Bioscience has no debt compared to 5 years ago when it was 23.8%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Lexaria Bioscience has less than a year of cash runway based on current free cash flow.
  • Lexaria Bioscience has less than a year of cash runway if free cash flow continues to grow at historical rates of 51.8% each year.
X
Financial health checks
We assess Lexaria Bioscience's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Lexaria Bioscience has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

LXX Dividends

 What is Lexaria Bioscience's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Lexaria Bioscience dividends.
If you bought CA$2,000 of Lexaria Bioscience shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Lexaria Bioscience's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Lexaria Bioscience's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:LXX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
Canada Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.1%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

CNSX:LXX Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2021-08-31
2020-08-31
2019-09-22
2019-08-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Lexaria Bioscience has not reported any payouts.
  • Unable to verify if Lexaria Bioscience's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Lexaria Bioscience's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Lexaria Bioscience has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Lexaria Bioscience's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Lexaria Bioscience afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Lexaria Bioscience has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

LXX Management

 What is the CEO of Lexaria Bioscience's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Chris Bunka
COMPENSATION $1,356,269
AGE 57
TENURE AS CEO 12.6 years
CEO Bio

Mr. Christopher A. Bunka, also known as Chris, serves as the Chairman, Chief Executive Officer, President and Secretary of Drift Capital Corp. Mr. Bunka serves as the President and a Director of CAB Financial Services Ltd. Since 1988, Mr. Bunka has been the CEO of CAB Financial Services Ltd., a private holding company located in Kelowna, Canada. He has been the Chairman and Chief Executive Officer of Lexaria Bioscience Corp. since October 26, 2006 and February 14, 2007, respectively. He served as Treasurer and Secretary of Lexaria Bioscience Corp. since February 2007 and as its Interim Chief Financial Officer since April 29, 2016. He served as the President of Lexaria Bioscience Corp., from October 26, 2006 to March 2015. He served as the Chief Executive Officer of Enertopia Corp until 2013. at Target Energy Inc. (AKA Golden Aria Corp.) from March 1, 2005 to July 23, 2013 and served as its Chief Financial Officer since February 14, 2007 and also served as its Principal Accounting Officer, Secretary and Treasurer. He is a venture capitalist and corporate consultant and has over 15 years executive management experience. He served as Treasurer of Lexaria Bioscience Corp., since February 2007 and also served as its Principal Accounting Officer. He served as the Chief Financial Officer of Lexaria Bioscience Corp. from February 14, 2007 to May 12, 2009. He served as Vice President of Edgetech Services Inc. From 1999 to 2002, he served as Chairman, President and Chief Executive Officer of Secure Enterprise Solutions Inc. He founded and served as Vice President of Secure Enterprise Solutions Inc. He was the founder of six private businesses in Canada and the USA since 1980 in diverse fields. He has been a Director of Lexaria Bioscience Corp. since November 2004. He serves as the Chairman of Golden Aria Corp. (Enertopia Corp.) and has been its Director since November 24, 2004. He served as a Director of Defiance Capital Corp. (AKA Defiance Silver Corp.) from July 31, 2007 to November 6, 2014. He is a Business Commentator and provided business updates to Vancouver radio station CKWX since 1998. He has written business and investment articles published in various North American publications and is also an international speaker and lecturer.

CEO Compensation
  • Chris's compensation has increased whilst company is loss making.
  • Chris's remuneration is higher than average for companies of similar size in Canada.
Management Team Tenure

Average tenure and age of the Lexaria Bioscience management team in years:

3.3
Average Tenure
50
Average Age
  • The tenure for the Lexaria Bioscience management team is about average.
Management Team

Chris Bunka

TITLE
Chairman & CEO
COMPENSATION
$1M
AGE
57
TENURE
12.6 yrs

John Docherty

TITLE
President & Director
COMPENSATION
$1M
AGE
50
TENURE
4.4 yrs

Allan Spissinger

TITLE
CFO, Corporate Secretary & Treasurer
COMPENSATION
$654K
AGE
50
TENURE
2.3 yrs

Alex Blanchard

TITLE
Manager Corporate Communications & Investor Relations

Ed Ergenzinger

TITLE
Chief Legal Advisor and Senior Advisor of Innovation
TENURE
0.8 yrs

Philip Ainslie

TITLE
Advisor & Consultant
Board of Directors Tenure

Average tenure and age of the Lexaria Bioscience board of directors in years:

0.4
Average Tenure
57
Average Age
  • The average tenure for the Lexaria Bioscience board of directors is less than 3 years, this suggests a new board.
Board of Directors

Chris Bunka

TITLE
Chairman & CEO
COMPENSATION
$1M
AGE
57
TENURE
12.9 yrs

John Docherty

TITLE
President & Director
COMPENSATION
$1M
AGE
50
TENURE
3.4 yrs

Nick Baxter

TITLE
Independent Director
COMPENSATION
$66K
AGE
65
TENURE
8.2 yrs

Ted McKechnie

TITLE
Independent Director
COMPENSATION
$82K
AGE
72
TENURE
4 yrs

Dwayne Godwin

TITLE
Member of Scientific Advisory Board
TENURE
0.4 yrs

Terry Blumenthal

TITLE
Member of Scientific Advisory Board
TENURE
0.4 yrs

Matthew Fraser

TITLE
Member of Scientific Advisory Board
TENURE
0.4 yrs

Carla Tome

TITLE
Member of Scientific Advisory Board
TENURE
0.4 yrs

Brian Quigley

TITLE
Director
AGE
45
TENURE
0.1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
X
Management checks
We assess Lexaria Bioscience's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Lexaria Bioscience has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

LXX News

Simply Wall St News

LXX Company Info

Description

Lexaria Bioscience Corp. focuses on the development of its proprietary nutrient infusion technologies for the production of superfoods. It operates in two segments, Intellectual Property Licensing and Consumer Products. The company develops and licenses DehydraTECH, a patented lipid nutrient infusion technology that improves taste, rapidity, and delivery of bioactive compounds that include cannabinoids, vitamins, NSAIDs, nicotine, and other molecules. It is also involved in the development, production, and distribution of enhanced functional food and supplement products under the ViPova and Lexaria Energy brands. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was founded in 2004 and is based in Kelowna, Canada.

Details
Name: Lexaria Bioscience Corp.
LXX
Exchange: CNSX
Founded: 2004
$67,918,441
78,637,134
Website: http://www.lexariabioscience.com
Address: Lexaria Bioscience Corp.
740 McCurdy Road,
Suite 100,
Kelowna,
British Columbia, V1X 2P7,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OTCPK LXRP Common Shares Pink Sheets LLC US USD 25. Sep 2006
CNSX LXX Common Shares Canadian National Stock Exchange CA CAD 25. Sep 2006
Number of employees
Current staff
Staff numbers
0
Lexaria Bioscience employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/22 00:33
End of day share price update: 2019/09/20 00:00
Last estimates confirmation: 2019/09/17
Last earnings filing: 2019/07/08
Last earnings reported: 2019/05/31
Last annual earnings reported: 2018/08/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.